Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?

Ann-Jean C C BeckJacobien M KiefferValesca P RetèlLydia F J van OverveldRobert P TakesMichiel W M van den BrekelWim H van HartenMartijn M Stuiver

Published in: PloS one (2019)

Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients.

Keyphrases

high resolution
end stage renal disease
high density
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes